Genetic predisposition to skin cancer

Current Opinion in Oncology

Volumn 11, Issue 2, 1999, Pages 132-138

  Halpern, Allan C ^a   Altman, Jamie F ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASAL CELL NEVUS SYNDROME; CANCER GENETICS; CANCER RISK; CANCER SUSCEPTIBILITY; DNA DAMAGE; DNA REPAIR; DYSPLASTIC NEVUS; FAMILIAL CANCER; GENE CONTROL; GENE THERAPY; GENETIC PREDISPOSITION; GENETIC SCREENING; HUMAN; MELANOMA; MULTIPLE CANCER; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SKIN CANCER; ULTRAVIOLET RADIATION; XERODERMA PIGMENTOSUM;

BASAL CELL NEVUS SYNDROME; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DROSOPHILA PROTEINS; DYSPLASTIC NEVUS SYNDROME; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INSECT PROTEINS; MODELS, BIOLOGICAL; RISK ASSESSMENT; SKIN NEOPLASMS; XERODERMA PIGMENTOSUM;

EID: 0032995702     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199903000-00010     Document Type: Review

References (49)

1. Atillasoy ES, Seykora JT, Soballe PW, Elenitsas R, Nesbit M, Elder DE, et al.: UVB induces atypical melanocytic lesions and melanoma in human skin. Am J Pathol 1998, 152:1179-1186.
2. Grossman D, Leffell DJ: The molecular basis of nonmelanoma skin cancer: new understanding [review]. Arch Dermatol 1997, 133:1263-1270. This paper is an excellent review of the current status of molecular and genetic processes in non-melanoma skin cancer.
3. Gorlin RJ: Nevoid basal-cell carcinoma syndrome [review]. Medicine 1987, 66:98-113.
4. Gailani MR, Bale SJ, Leffell DJ, DiGiovanna JJ, Peck GL, Poliak S, et al.: Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell 1992, 69:111-117.
5. Hahn H, Wicking C, Zaphiropoulous PG, Gailani MR, Shanley S, Chidambaram A, et al.: Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996, 85:841-851.
6. Johnson RL, Rothman AL, Xie J, Goodrich LV, Bare JW, Bonifas JM, et al.: Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996, 272:1668-1671.
7. Gailani MR, Bale AE: Developmental genes and cancer: role of patched in basal cell carcinoma of the skin [review]. J Natl Cancer Inst 1997, 89:1103-1109. An excellent review on the patched gene in basal cell carcinomas is presented in this paper.
8. Riddle RD, Johnson RL, Laufer E, Tabin C: Sonic hedgehog mediates the polarizing activity of the ZPA. Cell 1993, 75:1401-1416.
9. Roelink H, Porter JA, Chiang C, Tanabe Y, Chang DT, Beachy PA, Jessell TM: Floor plate and motor neuron induction by different concentrations of the amino-terminal cleavage product of sonic hedgehog autoproteolysis. Cell 1995, 81:445-455.
10. Dahmane N, Lee J, Robins P, Heller P, Ruiz I, Altaba A: Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours. Nature 1997, 389:876-881.
11. Xie J, Murone M, Luoh SM, Ryan A, Gu Q, Zhang C, et al.: Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998, 391:90-92.
12. Oro AE, Higgins KM, Hu Z, Bonifas JM, Epstein EH Jr, Scott MP: Basal cell carcinomas in mice overexpressing sonic hedgehog. Science 1997, 276:817-821.
13. Fan H, Oro AE, Scott MP, Khavari PA: Induction of basal cell carcinoma features in transgenic human skin expressing Sonic Hedgehog. Nat Med 1997, 3:788-792.
14. Aszterbaum M, Rothman A, Johnson RL, Fisher M, Xie J, Bonifas JM, et al.: Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J Invest Dermatol 1998, 110:885-888.
15. Clark WH Jr, Reimer RR, Greene M, Ainsworth AM, Mastrangelo MJ: Origin of familial malignant melanomas from heritable melanocytic lesions. The B-K syndrome. Arch Dermatol 1978, 114:732-738.
16. Lynch HT, Frichot BC III, Lynch JF: Familial atypical multiple molemelanoma syndrome. J Med Genet 1978, 15:352-356.
17. Greene MH, Clark WH Jr, Tucker MA, Kraemer KH, Elder DE, Fraser MC: High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med 1985, 102:458-465.
18. Tucker MA, Halpern A, Holly EA, Hartge P, Elder DE, Sagebiel RW, et al.: Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997, 277:1439-1444.
19. Bale SJ, Dracopoli NC, Tucker MA, Clark WH Jr, Fraser MC, Stanger BZ, et al.: Mapping the gene for hereditary cutaneous malignant melanomadysplastic nevus to chromosome 1p N Engl J Med 1989, 320:1367-1372. [Published erratum appears in N Engl J Med 1991,324:925.]
20. Goldstein AM, Dracopoli NC, Engelstein M, Fraser MC, Clark WH Jr, Tucker MA: Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Am J Hum Genet 1994, 54:489-496.
21. Cannon-Albright LA, Goldgar DE, Meyer LJ, Lewis CM, Anderson DE, Fountain JW, et al.: Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 1992, 258:1148-1152.
22. Gruis NA, Sandkuijl LA, Weber JL, Van der Zee A, Borgstein AM, Bergman, W, Frants RR: Linkage analysis in Dutch familial atypical multiple molemelanoma (FAMMM) syndrome families. Effect of naevus count. Melanoma Res 1993, 3:271-277.
23. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al.: A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994, 264:436-440.
24. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994, 368:753-756.
25. Quelle DE, Zindy F, Ashmun RA, Sherr CJ: Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995, 83:993-1000.
26. Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D: A novel p16INK4A transcript. Cancer Res 1995, 55:2995-2997.
27. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, et al.: Complex structure and regulation of the P16 (MTS1) locus. Cancer Res 1995, 55:2988-2994.
28. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, Depinho RA: Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996, 85:27-37.
29. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993, 366:704-707.
30. Haluska FG, Hodi FS: Molecular genetics of familial cutaneous melanoma [review]. J Clin Oncol 1998, 16:670-682. This is an excellent review emphasizing the importance of the role of the p16 gene in melanoma.
31. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, et al.: Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996, 12:97-99.
32. Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, et al.: Prevalence of pl 6 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 1998, 7:209-216. [Published erratum appears in Hum Mol Genet 1998 7:941].
33. Keller-Melchior R, Schmidt R, Piepkorn M: Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions. J Invest Dermatol 1998, 110:932-938.
34. Talve L, Sauroja I, Collan Y, Punnonen K, Ekfors T: Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int J Cancer 1997, 74:255-259.
35. Roth M, Boyle JM, Muller H: Thymine dimer repair in fibroblasts of patients with dysplastic naevus syndrome (DNS). Experientia 1988, 44:169-171.
36. Yarosh D, Klein J, Kibitel J, Alas L, O'Connor A, Cummings B, et al.: Enzyme therapy of xeroderma pigmentosum: safety and efficacy testing of T4N5 liposome lotion containing a prokaryotic DNA repair enzyme. Photodermatol Photoimmunol Photomed 1996, 12:122-130.
37. Kraemer KH, Levy DD, Parris CN, Gozukara EM, Moriwaki S, Adelberg S, Seidman MM: Xeroderma pigmentosum and related disorders: examining the linkage between defective DNA repair and cancer [review]. J Invest Dermatol 1994, 103:96S-101S.
38. Cleaver JE: Defective repair replication of DNA in xeroderma pigmentosum. Nature 1968, 218:652-656.
39. Copeland NE, Hanke CW, Michalak JA: The molecular basis of xeroderma pigmentosum [review]. Dermatol Surg 1997, 23:447-455. This article is a good review of the molecular processes involved in XP.
40. Lambert WC, Kuo HR, Lambert MW: Xeroderma pigmentosum [review]. Dermatol Clin 1995, 13:169-209.
41. Svoboda DL, Briley LP, Vos JM: Defective bypass replication of a leading strand cyclobutane thymine dimer in xeroderma pigmentosum variant cell extracts. Cancer Res 1998, 58:2445-2448.
42. Cordeiro-Stone M, Zaritskaya LS, Price LK, Kaufmann WK: Replication fork bypass of a pyrimidine dimer blocking leading strand DNA synthesis. J Biol Chem 1997, 272:13945-13954.
43. Kraemer KH, Lee MM, Scotto J: Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol 1987, 123:241-250.
44. Smith R, Healy E, Siddiqui S, Flanagan N, Steijlen PM, Rosdahl I, et al.: Melanocortin 1 receptor variants in an Irish population. J Invest Dermatol 1998, 111:119-122.
45. Chidambaram A, Goldstein AM, Gailani MR, Gerrard B, Bale SJ, DiGiovanna JJ, et al.: Mutations in the human homologue of the Drosophila patched gene in Caucasian and African-American nevoid basal cell carcinoma syndrome patients. Cancer Res 1996, 56:4599-4601.
46. Unden AB, Holmberg E, Lundh-Rozell B, Stahle-Backdahl M, Zaphiropoulos, PG, Toftgard R, Vorechovsky I: Mutations in the human homologue of Drosophila patched (PTCH) in basal cell carcinomas and the Gorlin syndrome: different in vivo mechanisms of PTCH inactivation. Cancer Res 1996, 56:4562-4565.
47. Gailani MR, Stahle-Backdahl M, Leffell DJ, Glynn M, Zaphiropoulos PG, Pressman C, et al.: The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet 1996, 14:78-81.
48. Wicking C, Shanley S, Smyth I, Gillies S, Negus K, Graham S, et al.: Most germ-line mutations in the nevoid basal cell carcinoma syndrome lead to a premature termination of the PATCHED protein, and no genotype-phenotype correlations are evident. Am J Hum Genet 1997, 60:21-26.
49. Stone DM, Hynes M, Armanini M, Swanson TA, Gu Q Johnson RL, et al.: The tumour-suppressor gene patched encodes a candidate receptor for Sonic hedgehog. Nature 1996, 384:129-134.